Minervax

About

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

Hellerup,Hovedstaden,Denmark
1 - 10
http://minervax.com/

Highlights

Details

Last Funding Type: Series C
Last Funding Money Raised: €22M
Industries: Biotechnology,Health Care,Life Science,Medical,Wellness
Founded date: Jan 1, 2010
Number Of Employee: 1 - 10
Operating Status: Active
Legal Name: Minervax ApS

Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

12

€135.90M kr22.50M

Minervax has raised a total of €135.90M kr22.50M in funding over 2 rounds. Their latest funding was raised on Dec 15, 2022 from a Series C round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 15, 2022	Series C	€22M	9	Pureos Bioventures Trill Impact	—	Detail
Dec 15, 2022	Debt Financing	€50M	1	European Investment Bank	—	Detail
Dec 15, 2020	Series B	€47.40M	7	Wellington Partners	—	Detail
Sep 8, 2020	Series Unknown	—	1	—	—	Detail
Jan 21, 2019	Grant	€4.40M	3	Novo Holdings Repair Impact Fund	—	Detail

Investors

Number of Lead Investors

Number of Investors

8

16

Minervax is funded by 16 investors. Pureos Bioventures and Trill Impact are the most recent investors.

Investor Name	Lead Investor	Funding Round
Pureos Bioventures	Yes	Series C
Trill Impact	Yes	Series C
European Investment Bank	Yes	Debt Financing
Novo Holdings	Yes	Grant
Adjuvant Capital	—	Series C
Industrifonden	—	Series C
LF Investment	—	Series C
Repair Impact Fund	—	Series C
Sanofi Ventures	—	Series C
Sunstone Life Science Ventures	—	Series C